Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. EHA 2023;Abstract S145.
Brown JR et al. Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia (CLL) patients: Results from the Phase I/II BRUIN study. EHA 2023;Abstract S146.
Caimi PF et al. Long-term responses with loncastuximab tesirine: Updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large B-cell lymphoma. EHA 2023;Abstract P1132.
Dickinson M et al. Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study. ICML 2023;Abstract 095.
Herrera AF et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). ASCO 2023;Abstract LBA4.
Jacobson CA et al. Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL). ASCO 2023;Abstract 7509.
Jain P et al. Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma—A phase II clinical trial. ICML 2023;Abstract 099.
Jurczak W et al. Longer follow-up from the pivotal EPCORE NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large B-cell lymphoma. EHA 2023;Abstract P1118.
Kater A et al. Final 7-year follow up and retreatment substudy analysis of MURANO: Venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). EHA 2023;Abstract S201.
Kater A et al. Genetic alterations and outcomes with fixed-duration ibrutinib+venetoclax (ibr+ven): Results from the phase 3 GLOW study in patients with previously untreated CLL. EHA 2023;Abstract P620.
Kittai A et al. A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL). ASCO 2023;Abstract 7540.
Langerbeins P et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): Final results of the phase 3, double-blind, placebo-controlled CLL12 trial. EHA 2023;Abstract S200.
Merryman R et al. Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. ASCO 2023;Abstract 7506.
Morschhauser F et al. TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL). ICML 2023;Abstract LBA4.
Munir T et al. Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Extended follow-up of the SEQUOIA study. EHA 2023;Abstract P639.
Nair R et al. High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study. ASCO 2023;Abstract 7524.
Nastoupil LJ et al. Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy. ASCO 2023;Abstract 7526.
Shah NN et al. Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment. ASCO 2023;Abstract 7514.
Shen LH et al. Mosunetuzumab demonstrates durable responses in patients with relapsed/refractory follicular lymphoma and ≥2 prior therapies: Updated analysis of a pivotal phase II study. EHA 2023;Abstract P1078.
Siddiqi T et al. Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. ASCO 2023;Abstract 7501.
Taszner M et al. Odronextamab in patients with relapsed/refractory follicular lymphoma Grade 1–3a: Results from a prespecified analysis of the pivotal Phase 2 study ELM-2. EHA 2023;Abstract P1083.
Walewski J et al. Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from a prespecified analysis of the pivotal phase 2 study ELM-2. EHA 2023;Abstract P1115.
Wang M et al. Lisocabtagene maraleucel (liso-cel) in R/R MCL: Primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design TRANSCEND NHL 001 study. ICML 2023;Abstract LBA3.
Westin J et al. Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma. ASCO 2023;Abstract LBA107.